SCHEMBL3339775

SCHEMBL3339775

CC(C)(C)c1cc(=O)o[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.41
ALDH1A1 P00352 2/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
BLM P54132 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PLG P00747 1/20 0.32
ABCC9 O60706 1/20 0.32
ABCC8 Q09428 1/20 0.32
KCNJ11 Q14654 1/20 0.32
KCNJ8 Q15842 1/20 0.32
GABRP O00591 2/20 0.31
GABRD O14764 2/20 0.31
GABRA1 P14867 2/20 0.31
GABRB1 P18505 2/20 0.31
GABRG2 P18507 2/20 0.31
GABRB3 P28472 2/20 0.31
GABRA5 P31644 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL179494 0.63 GABRA1 (0.43) DAOLMNAMAPTPLGGABRP
SCHEMBL179486 0.62 DAO (0.60) DAOALDH1A1LMNAPOLBMAPT
SCHEMBL6671097 0.60
SCHEMBL571512 0.59 DAO (0.40) DAOALDH1A1LMNAPOLBMAPT
SCHEMBL15474293 0.59 DAO (0.35) DAOALDH1A1KDM4EGLAGAA
SCHEMBL7764663 0.59 CA1 (0.56) DAOALDH1A1LMNAKDM4EGLA
SCHEMBL18701493 0.57 CA1 (0.43) DAOALDH1A1LMNAPOLBMAPT
SCHEMBL10256269 0.57 GABRA1 (0.41) DAOALDH1A1LMNAPOLBMAPT
SCHEMBL13268569 0.57 GPR84 (0.47) DAOGABRA1GABRB2
SCHEMBL21305806 0.56 ALDH1A1 (0.50) DAOALDH1A1LMNAPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10442828-B2 Kinase inhibitors TOPIVERT PHARMA LIMITED (GB) 2019-10-15 US disclosed
US-9839639-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-12-12 US disclosed
US-20170291917-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2017-10-12 US disclosed
US-20170291917-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2017-10-12 US disclosed
US-20170189399-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-07-06 US disclosed
US-20170144971-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC. (US) 2017-05-25 US disclosed
US-20100105814-A1 ULTRAVIOLET ABSORBENT AND POLYMER MATERIAL CONTAINING THE SAME FUJIFILM CORPORATION (JP) 2010-04-29 US disclosed
EP-0824720-B1 ACID BLEACHABLE DYE CONTAINING LITHOGRAPHIC PRINTING PLATE COMPOSITION MINNESOTA MINING & MFG (US) 1999-09-22 EP disclosed
EP-0824720-A1 ACID BLEACHABLE DYE CONTAINING LITHOGRAPHIC PRINTING PLATE COMPOSITION MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-02-25 EP disclosed
US-5665522-A Visible image dyes for positive-acting no-process printing plates MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-09-09 US disclosed
WO-1996035143-A1 ACID BLEACHABLE DYE CONTAINING LITHOGRAPHIC PRINTING PLATE COMPOSITION MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1996-11-07 WO disclosed
EP-0412379-B1 Silver halide colour photographic light-sensitive materials FUJI PHOTO FILM CO LTD (JP) 1996-05-15 EP disclosed
EP-0412379-A1 Silver halide colour photographic light-sensitive materials FUJI PHOTO FILM CO., LTD. (JP) 1991-02-13 EP disclosed
EP-0125253-A1 A PROCESS FOR THE PREPARATION OF 3-HYDROXY-ISOXAZOLOLE A/S CHEMINOVA (DK) 1984-11-21 EP disclosed
WO-1984001774-A1 A PROCESS FOR THE PREPARATION OF 3-HYDROXY-ISOXAZOLOLE CHEMINOVA AS (DK) 1984-05-10 WO disclosed
EP-0010262-B1 PROCESS FOR PREPARING 3-AMINO-5-T-BUTYLISOXAZOLE SHIONOGI & CO., LTD. (JP) 1983-01-26 EP disclosed
US-4256899-A REACTING PIVALOYLACETONITRILE WITH HYDROXYLAMINE, TREATING WITH A MINERAL ACID SHIONOGI & CO., LTD. (JP) 1981-03-17 US disclosed
EP-0010262-A1 Process for preparing 3-amino-5-t-butylisoxazole SHIONOGI & CO., LTD. (JP) 1980-04-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105814-A1 ULTRAVIOLET ABSORBENT AND POLYMER MATERIAL CONTAINING THE SAME UGT1A6, MCM6, MSH6 DAO 3716/4885ALDH1A1 1776/4885LMNA 3592/4885
US-10442828-B2 Kinase inhibitors SYK, LTK, LTB4R DAO 3015/4885ALDH1A1 4550/4885LMNA 4232/4885
US-20170291917-A1 KINASE INHIBITORS SYK, LYN, BTK DAO 3296/4885ALDH1A1 4786/4885LMNA 4562/4885
US-20170144971-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer MDM2, TP53, CDKN1A DAO 4144/4885ALDH1A1 332/4885LMNA 2556/4885
US-20170189399-A1 NEPRILYSIN INHIBITORS MME, REN, ACE DAO 2586/4885ALDH1A1 2655/4885LMNA 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.